Our previous studies have shown that human anti-c-Met scFv can target c-Met protein on tumor cells, while c-Met-IgG bound to oxaliplatin can significantly target c-Met positive HCC cells and reduce the side effects of preclinical models of HCC (32). The gene discussed is MET; the disease is neoplasm.